相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability
Mbarka Bchetnia et al.
JOURNAL OF MEDICAL GENETICS (2021)
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Antonio J. Vallejo-Vaz et al.
LANCET (2021)
Tobacco Use Prevalence and Transitions From 2013 to 2018 Among Adults With a History of Cardiovascular Disease
Lindsay M. Reynolds et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease A Systematic Review and Meta-Analysis
Pengwei Hu et al.
CIRCULATION (2020)
Evinacumab in Patients with Refractory Hypercholesterolemia
Robert S. Rosenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia
Sofia Perez-Calahorra et al.
ATHEROSCLEROSIS (2019)
Cigarette consumption estimates for 71 countries from 1970 to 2015: systematic collection of comparable data to facilitate quasi-experimental evaluations of national and global tobacco control interventions
Steven J. Hoffman et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Simplified Canadian Definition for Familial Hypercholesterolemia
Isabelle Ruel et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
Paul M. Ridker et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Society Position Statement Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018
Liam R. Brunham et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia
G. Kees Hovingh et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
Leo E. Akioyamen et al.
BMJ OPEN (2017)
Prediction of cardiovascular risk in patients with familial hypercholesterolaemia
Guillermo Villa et al.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2017)
Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype
Amanda M. Perak et al.
CIRCULATION (2016)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
The LDL Receptor
Joseph L. Goldstein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Long-term safety and efficacy of high-dose Atorvastatin treatment in patients with familial hypercholesterolemia
S van Wissen et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf et al.
LANCET (2004)
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia
C Gagné et al.
CIRCULATION (2002)
The value of isolated populations
S Shifman et al.
NATURE GENETICS (2001)
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial
TJ Smilde et al.
LANCET (2001)
分享论文
